sector medic suppli devic
messag ew top consensu top bottom line yet
second straight quarter modest tavr miss spoil parti unlik
blame math suggest shortfal driven entir edward
eu tavr busi current competit dynam market somewhat
concern believ fixat one data point would mistak especi
new product way label expans still come
rais pt reiter buy rate
cc came consensu manag elect
provid revenu split geographi math suggest sale actual met
street expect roughli would repres acceler
growth ou tavr anoth stori revenu deceler
cc cc manag attribut weak share loss
result increasingli aggress price strategi competitor rather play
along game edward hope best-in-class technolog speak
centera set re-launch sapien ultra still track receiv ce mark
yearend whether approach work european tavr center continu
vote wallet remain seen believ patienc warrant
particularli tavr growth bounc back disappoint manag
continu expect ultra receiv fda approv end year well
could give edward ad momentum head present march
manag maintain prior guidanc ww tavr revenu come
high end origin rang underli growth forecast
model call full year tavr sale cc
elsewher often-overlook critic busi post anoth strong
quarter revenu cc come ahead consensu
strength larg driven edward hemospher platform continu
build momentum compani begin roll acumen hypotens predict
hpi softwar later year acumen util predict analyt alert hospit
staff risk low blood pressur event minut ahead incid
differenti featur believ like well receiv model
call sale cc manag growth guidanc
meanwhil heart valv therapi continu exceed reduc expect
revenu rose cc consensu edward savr volum
pressur rise tavr penetr compani continu benefit
posit mix driven adopt recent introduc inspiri resilia
product continu believ ramp tavr adopt eventu appli
signific pressur edward surgic valv busi howev remain impress
compani abil leverag innov stay ahead wave
manag continu expect sale come high end
guidanc rang model call revenu cc
top line solid oper leverag tax drove earn upsid edward
report gross margin yoy consensu
posit product mix off-set headwind fx continu invest
futur manufactur capac sg spend rose yoy sale
came street expect expens increas yoy
sale consensu combin drove ebita margin
yoy street project line lower
expect tax rate vs consensu ad earn howev ep
still top consensu exclud benefit continu page
page analyst certif import disclosur
pipelin front edward tmvr/ttvr portfolio continu make slow
steadi progress european cardioband sale remain stuck neutral process
integr product compani broader manufactur oper continu
crimp suppli howev despit gener revenu first half
year manag maintain guidanc impli long await
commerci ramp may final upon us continu view cardioband product
potenti becom first-lin therapi treatment mitral tricuspid
regurgit edward receiv ce mark approv tr indic
elsewher enrol clasp trial evalu pascal edge-to-edg repair system
on-going edward continu target eu launch product visibl
potenti regulatori timelin rest compani portfolio remain limit
harpoon chordal replac forma tricuspid spacer undergo
redesign manag still readi commit one two mitral replac
program tmvr front ceo mike mussallem note product make
good progress first forg ahead pivot trial
involv transap tmvr system edward remain focus develop
transsept approach someth believ prerequisit widespread adopt
guidanc move higher conjunct releas edward rais
outlook adjust ep driven
combin lower tax rate improv oper leverag meanwhil manag
continu expect total revenu come high end rang
model call adjust ep total revenu
organ compar prior estim respect
long-term confid edward growth runway remain unchang
mark inconsist tavr perform see potenti easier
comp new product launch centera ultra cardioband resilia drive improv
momentum back half year ahead next leg tavr market expans
rais dcf-deriv price target
signific upsid potenti target current level reiter buy rate
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale came cc edward busi
gener revenu cc work suggest tavr market
track least doubl next five year edward pois primari
beneficiari growth even competit increas meanwhil compani robust
pipelin potenti extend growth runway well next decad view
emerg opportun expand tavr applic beyond sever
symptomat aortic stenosi popul develop equal compel new market
transcathet treatment mitral tricuspid valv diseas visibl new
growth driver improv expect investor confid edward long-term growth
potenti increas support premium valuat stock
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium valuat also make
compani difficult valu base tradit metric result employ
discount cash flow methodolog deriv price target assum
wacc termin growth rate calcul forward npv per share
previous equat multipl previous
forward ntm ep estim signific upsid potenti price
target current level assign edward buy rate
downsid risk rate price target includ tavr market growth fall
short street expect greater-than-expect share gain new tavr
competitor come market clinic and/or regulatori setback pipelin
program caus investor question sustain edward premium growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
